NAVISTAR THERMOCOOL DEFLECTABLE DIAGNOSTIC/ABLATION CATHETER
Biosense Webster, Inc. · Decision date Aug 11, 2006
What did the FDA approve?
FDA approved the NAVISTAR THERMOCOOL deflectable diagnostic/ablation catheters, covering models N175TBH, N175TCH, N175TDH, N175TFH, N175TCBH, N175TCCH, N175TCDH, N175TCFH, and N175TCJH. The approval states that these catheters, used with the Stockert 70 RF generator, are indicated for treating recurrent drug/device refractory sustained monomorphic ventricular tachycardia due to prior myocardial infarction in adults.
The same statement reports that the catheter provides location information when used with the CARTO EP/XP navigation system and can be used for catheter-based cardiac electrophysiological mapping, including stimulation and recording. The source does not include supplement type or reason fields, so no information is available about whether this decision modified an earlier submission or represented the original approval scope.
FDA approval order statement
APPROVAL FOR THE NAVISTAR THERMOCOOL DEFLECTABLE DIAGNOSTIC/ABLATION CATHETERS WHICH INCLUDE MODELS N175TBH, N175TCH, N175TDH, N175TFH, N175TCBH, N175TCCH, N175TCDH, N175TCFH, AND N175TCJH. THE NAVISTAR THERMOCOOL DIAGNOSTIC/ABLATION DEFLECTABLE TIP CATHETER AND RELATED ACCESSORY DEVICES, WHEN USED WITH THE STOCKERT 70 RADIOFREQUENCY (RF) GENERATOR, ARE INDICATED FOR THE TREATMENT OF RECURRENT DRUG/DEVICE REFRACTORY SUSTAINED MONOMORPHIC VENTRICULAR TACHYCARDIA (VT) DUE TO PRIOR MYOCARDIAL INFARCTION (MI) IN ADULTS.THE NAVISTAR THERMOCOOL CATHETER PROVIDES LOCATION INFORMATION WHEN USED WITH THE CARTO EP / XP NAVIGATION SYSTEM, AND CAN BE USED FOR CATHETER-BASED CARDIAC ELECTROPHYSIOLOGICAL MAPPING (STIMULATION AND RECORDING).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 11, 2006
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P040036
- Regulatory pathway
- Premarket approval application
- Applicant
- Biosense Webster, Inc.
- Product code
- LPB
- Decision code
- APPR
- Decision date
- Aug 11, 2006
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cardiac ablation percutaneous catheter.
- Applicant
- Biosense Webster, Inc.
- Product code
- LPB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P040036 received
Application receipt date recorded by FDA.
P040036 · FDA decision
APPR
P040036/S101 · Related supplement
THERMOCOOL SMARTTOUCH BI-DIRECTIONAL NAVIGATION CATHETER; THERMOCOOL SMARTTOUCH UNI-DIRECTIONAL NAVIGATION CATHETER
Timeline entries are records held by MedtechLedger for P040036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Explore the linked device profile
Other records with product code LPB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Irvine Biomedical, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
| Irvine Biomedical, Inc. | PMA approval | Jan 14, 2005 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P040036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records